Drugs · acquisition-cost intelligence
Meropenem
· ingredient meropenem· MEROPENEM 1 g/1; MEROPENEM 1 g/20mL; MEROPENEM 1 g/30mL; MEROPENEM 1 g/50mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.44
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Medicare Part D coverage · CY2026
On 327 plan formularies · typical tier 3
Prior auth 6% · Step therapy 0% · Quantity limit 9% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.